Immunomodulatory effect of esomeprazole antitumoral and high-dose under neoadjuvant and adjuvant in patients with melanoma in stage III. Randomized pilot study treatment vs control (EFFETTO IMMUNOMODULATORIO E ANTITUMORALE DELL'ESOMEPRAZOLO AD ALTE DOSI IN REGIME NEOADIUVANTE E ADIUVANTE IN PAZIENTI CON MELANOMA IN STADIO III. STUDIO PILOTA RANDOMIZZATO TRATTAMENTO VS CONTROLLO)

Trial Profile

Immunomodulatory effect of esomeprazole antitumoral and high-dose under neoadjuvant and adjuvant in patients with melanoma in stage III. Randomized pilot study treatment vs control (EFFETTO IMMUNOMODULATORIO E ANTITUMORALE DELL'ESOMEPRAZOLO AD ALTE DOSI IN REGIME NEOADIUVANTE E ADIUVANTE IN PAZIENTI CON MELANOMA IN STADIO III. STUDIO PILOTA RANDOMIZZATO TRATTAMENTO VS CONTROLLO)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms AdESOM
  • Most Recent Events

    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top